Chugai Pharmaceutical Co., Ltd.
CHGCY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.24 | -375.68 | 4.63 | -1.89 |
| FCF Yield | 0.59% | 0.75% | 0.40% | 1.34% |
| EV / EBITDA | 58.48 | 86.49 | 78.81 | 70.52 |
| Quality | ||||
| ROIC | 6.67% | 4.54% | 5.07% | 4.59% |
| Gross Margin | 69.91% | 69.63% | 69.55% | 68.78% |
| Cash Conversion Ratio | 0.66 | 1.23 | 0.69 | 1.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -11.56% | -1.28% | 0.29% | -2.42% |
| Free Cash Flow Growth | -99.53% | 107.70% | -70.79% | 43.79% |
| Safety | ||||
| Net Debt / EBITDA | -2.52 | -3.63 | -3.09 | -3.44 |
| Interest Coverage | 3,088.74 | 2,240.05 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.41 | 0.37 | 0.38 | 0.39 |
| Cash Conversion Cycle | 245.56 | 258.86 | 258.47 | 266.33 |